

# Risk Management Plan Creation

## Best Practice in Medical Writing of the EU-RMP (GVP Module V)

### Virtual Live Training Course

24-26 September 2024 13:00-17:30 CEST

#### OVERVIEW

This virtual live course is aimed at the practical aspects of the EU Risk Management Plan (EU-RMP) creation process. It will provide a detailed understanding of the GVP Module V (Rev 2) and the Guidance on the format of the RMP with all potential implications for the marketing authorisation holders.

The participants will learn the best practice in medical writing of the EU-RMP. The solutions will be demonstrated in practical exercises included throughout the course.

#### LEARNING OBJECTIVES

At the conclusion of this virtual live course, participants will be able to:

- Follow requirements of the GVP Module V and Guidance on the format of the RMP
- Define the best medical writing practices for EU-RMP and consistency check with other parts of the dossier
- Identify the project management challenges

#### KEY TOPICS

- Background to the EU Risk Management
- Objectives and Structure of the EU-RMP
- Product and Disease/Condition Overviews
- Safety Specification Modules SII-SVI
- Identification and Characterisation of Safety Concerns (Modules SVII and SVIII)
  - Group Work on Safety Concerns
- Source Data and Planning Process
  - Group Work on Project Management
- Pharmacovigilance Plan and Post-Authorisation Efficacy Studies
- RMPs outside of the EU
- Summary of the EU-RMP and Annexes
- Risk Minimisation Measures
  - Group Work on Risk Minimisation
- EU-RMP for Generic Medicinal Products (and other "Article 10" Products)
- Publication of EU RMPs
- Preview of the GVP V Rev 3 and RMP Template Rev 3

#### WHO WILL ATTEND

This course is intended for the professionals working within the pharmaceutical industry in pharmacovigilance, drug safety, regulatory, and medical affairs or similar positions, who are involved in the medicinal product lifecycle.

This course would be especially beneficial for junior and medium level experience professionals involved in preparation of the EU-RMP and working within the pharmaceutical industry, as service providers, and/or research organisations.

#### FACULTY

##### **Klaudija Marijanovic Barac**

Senior Director, Teva Periodic Reports and Risk Management Centre (TPC), EU & UK QPPV Deputy  
Teva  
Croatia

##### **Emil Cochino**

Scientific Senior Specialist (Risk Management)  
European Medicines Agency (EMA)  
Netherlands

##### **Maria Escudeiro dos Santos**

Risk Management Specialist  
EMA  
Netherlands

## DAY 1

### 13:00 WELCOME AND INTRODUCTION OF FACULTY AND PARTICIPANTS

#### 13:15 SESSION 1

##### BACKGROUND TO THE EU RISK MANAGEMENT

*Emil Andrei Cochino and Maria Escudeiro dos Santos*

- Terminology
- History of RMP in the EU
- Legal framework in the EU

#### 14:00 SESSION 2

##### OBJECTIVES AND STRUCTURE OF THE EU-RMP

*Emil Andrei Cochino and Maria Escudeiro dos Santos*

- Structure and content of the RMP
- EU-RMP versus Periodic Benefit-Risk Evaluation Report (PBRER)
- RMP updates

#### 14:45 BREAK

#### 15:00 SESSION 3

##### PRODUCT AND DISEASE/CONDITION OVERVIEWS

*Klaudija Marijanovic Barac and Emil Andrei Cochino*

- Product/-s overview
- Indication/-s and target population/-s
- Epidemiology of the disease/condition
- Risk factors, comorbidities
- Natural history of the disease, main treatment options

#### 15:30 SESSION 4

##### SAFETY SPECIFICATION (MODULES SII-SVI)

*Klaudija Marijanovic Barac and Maria Escudeiro dos Santos*

- Key findings from the nonclinical development programme
- Clinical development programme and populations not studied
- Post-marketing experience

#### 16:00 SESSION 5

##### IDENTIFICATION AND CHARACTERISATION OF SAFETY CONCERNS (MODULES SVII AND SVIII)

*Emil Andrei Cochino*

- Identification of important identified/potential risks (important and non-important risks)
- Characterisation of identified and potential risks
- Safety concerns (points to consider)

#### 16:30 SESSION 6

##### GROUP WORK I - SAFETY CONCERNS

*Klaudija Marijanovic Barac and Emil Andrei Cochino*

#### 17:00 Q&A

#### 17:30 END OF DAY 1

## DAY 2

#### 13:00 SESSION 7

##### SOURCE DATA AND PLANNING PROCESS

*Klaudija Marijanovic Barac*

- Project plan
- Data sources (interdepartmental responsibilities)

#### 13:30 SESSION 8

##### GROUP WORK II - PROJECT MANAGEMENT

*Klaudija Marijanovic Barac, Emil Andrei Cochino and Maria Escudeiro dos Santos*

#### 14:15 BREAK

#### 14:30 SESSION 9

##### PHARMACOVIGILANCE PLAN AND POST-AUTHORISATION EFFICACY STUDIES

*Klaudija Marijanovic Barac and Maria Escudeiro dos Santos*

- Routine pharmacovigilance activities
- Additional pharmacovigilance activities
- Post-authorisation efficacy studies (PAES)

#### 15:30 SESSION 10

##### RISK MINIMISATION MEASURES

*Klaudija Marijanovic Barac and Emil Andrei Cochino*

- Routine risk minimisation measures
- Additional risk minimisation measures
- Evaluation of the effectiveness of risk minimisation measures

#### 16:15 SESSION 11

##### GROUP WORK III - RISK MINIMISATION

*Klaudija Marijanovic Barac and Emil Andrei Cochino*

#### 17:00 SESSION 12

##### SUMMARY OF THE EU-RMP AND ANNEXES

*Emil Andrei Cochino*

- Summary of the RMP
- Annexes to the EU-RMP

#### 17:30 END OF DAY 2

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.

## DAY 3

13:00 Q&A

14:00 SESSION 13

### RMPS OUTSIDE OF THE EU

*Klaudija Marijanovic Barac*

- ICH founding members (Japan, United States)
- Canada, Australia, United Kingdom, Switzerland
- Other countries

14:30 BREAK

14:45 SESSION 14

### EU-RMP FOR GENERIC MEDICINAL PRODUCTS (AND OTHER 'ARTICLE 10' PRODUCTS)

*Klaudija Marijanovic Barac*

- Specifics of RMPs for generic medicinal products
- HaRP project

15:45 SESSION 15

### PUBLICATION OF EU RMPS

*Klaudija Marijanovic Barac and Emil Andrei Cochino*

- Procedural guidance
- Protected Personal Data (PPD)
- Commercially Confidential Information (CCI)
- Drafting of the RMP
- Redaction of the RMP
- Q&A and practical examples

16:15 SESSION 16

### PREVIEW OF THE GVP V REV 3 AND RMP TEMPLATE REV 3

*Emil Andrei Cochino*

- ATMP focus
- Main changes proposed
- Timelines for consultation and publication
- Future legislative requirements

16:45 Q&A

17:30 END OF THE TRAINING COURSE

## Continuing Education

The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 10 credits.



## Technical Requirements

To test your system compatibility, please click on the link:  
<https://diaglobal.zoom.us/test>

For full system requirements, please visit the website:  
<https://www.diaglobal.org/General/System-Requirements>

## Group Discounts

**Register 3 individuals from the same company for the same course and receive complimentary registration for a 4th!**

- All 4 individuals must register and prepay at the same time – no exceptions
- DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership
- You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred.

Group registration is not available online and does not apply to the already discounted fees for industry (early-bird), government or charitable nonprofit/academia.

To take advantage of this offer, please print the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together via email to [basel@diaglobal.org](mailto:basel@diaglobal.org).

## Customized Professional Development for Your Team

Get a customized training for your department (or even across different departments!) and benefit from increased:

- Knowledge of a topic of your choice
- Flexibility & Convenience
- Cost Effectiveness

Or explore [eLearning](#) to allow self-paced learning.

For more information please contact [tereza.krucka@diaglobal.org](mailto:tereza.krucka@diaglobal.org)

Follow @DrugInfoAssn



REGISTRATION FORM | Virtual Live Training Course

EU RMP Creation #24545  
24-26 September 2024 13:00-17:30 CEST



REGISTRATION FEES

Registration fee includes admission to the full virtual live course, electronic access to training course material, access to course recordings. **Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material.**

Please check:

FEES	MEMBER EARLY-BIRD valid until 30 Jul 2024	MEMBER valid from 31 Jul 2024	NON-MEMBER
INDUSTRY / REPRESENTATIVE	€ 1'215.00 <input type="checkbox"/>	€ 1'350.00 <input type="checkbox"/>	€ 1'610.00 <input type="checkbox"/>
ACADEMIA/CHARITABLE/GOVERNMENT/NON-PROFIT (FULL-TIME)	NA	€ 675.00 <input type="checkbox"/>	€ 935.00 <input type="checkbox"/>
A special discount for SMEs on the standard fee is available for a limited number of places. To prove your status as an SME, a confirmation of the European Medicines Agency is necessary. Please contact DIA for more information.			

All registration fees are subject to VAT if applicable.

Please enter your company's VAT number: \_\_\_\_\_

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

Payment is due 30 days after registration and must be paid in full by commencement of the course.

DIA MEMBERSHIP

All nonmember fees include a one year DIA membership, at no additional cost. Explore membership benefits at [DIAglobal.org/Membership](https://diaglobal.org/Membership).

DIA membership will renew automatically at the end of the complimentary membership term, at the then current membership rates. You may cancel automatic membership renewal at any time by accessing your account online at [DIAglobal.org](https://diaglobal.org). If you would like to decline complimentary membership, please indicate your preference below.

☐ I would like to decline a one year complimentary DIA membership.

The DIA Contact Centre Team will be pleased to assist you with your registration from Monday to Friday between 09:00 and 17:00 CE(S)T. **Tel.** :+41 61 225 51 51

**Email:** [Basel@DIAglobal.org](mailto:Basel@DIAglobal.org) **Mail:** DIA, KÜchengasse 16, 4051 Basel, Switzerland

**Web:** [www.DIAglobal.org](https://www.DIAglobal.org)

TERMS AND CONDITIONS

Cancellation Policy

All cancellations must be made in writing and be received at the DIA office four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00

If you do not cancel four weeks prior to the event start date and do not attend, you will be responsible for the full registration fee.

DIA reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA office of any such substitutions as soon as possible.

Event Stream and Recording

If you attend a DIA event, we make video and audio recordings of events (both face-to-face and online) that may include your participation in the event, including your image, questions and comments. To view our full photography and video recording policy, click <https://www.diaglobal.org/General/Photography-Policy>.

Privacy Policy

DIA respects the privacy of all of its members and customers. To view our privacy policy, click <https://www.diaglobal.org/About-Us/Privacy-Policy>.

ATTENDEE DETAILS	PAYMENT METHOD		
<p>Please complete in block capital letters or attach the attendee's business card here.</p> <p><input type="checkbox"/> Prof <input type="checkbox"/> Dr <input type="checkbox"/> Ms <input type="checkbox"/> Mr</p> <p>_____</p> <p>Last Name</p> <p>_____</p> <p>First Name</p> <p>_____</p> <p>Job Title</p> <p>_____</p> <p>Company</p> <p>_____</p> <p>Address</p> <p>_____</p> <p>Postal Code</p> <p>_____</p> <p>City</p> <p>_____</p> <p>Country</p> <p>_____</p> <p>Telephone Number</p> <p>_____</p> <p>Attendee email required for course material access</p>	<p>DIA accepts only Credit Card as a payment method.</p> <p>Payments by VISA, Mastercard or AMEX are accepted. Other types of credit card are not accepted.</p> <p>You will receive a payment link in the coming days to complete the payment.</p> <p>Please complete payment within 7 days of receipt of the payment link.</p> <p>Payments will be net of all charges and bank charges will be borne by the payer.</p> <p><b>If you have not received your confirmation within five working days, please contact <a href="mailto:basel@diaglobal.org">basel@diaglobal.org</a>.</b></p> <p>By signing below, I confirm that I read and agree with DIA's Terms and Conditions of booking.</p> <p>These are available from the office or online by clicking: <a href="http://www.diaglobal.org/EUterms">http://www.diaglobal.org/EUterms</a></p> <table><tr><td>Date</td><td>Signature</td></tr></table>	Date	Signature
Date	Signature		